NEWS
Nursing Home COVID-19 Data are Getting Better
A large share of total COVID-19 deaths in the United States have occurred in nursing homes, prompting the Centers for Medicare & Medicaid Services (CMS) to begin reporting facility-level data on COVID-19 rates at nursing homes.
Maybe Every Good Turn Deserves A Tax Break
“The result of those changes is a 4 percent dip in total charitable giving, and, ‘for middle- to upper-middle-income tax filers, the doubling of the standard deduction is responsible for nearly all the change in giving,’ Alex Brill and Derrick Choe, both of the American Enterprise Institute, explained in a 2018 analysis.”
COVID-19 and Nursing Homes: Examining New National Data
The first widely reported COVID-19 deaths in the United States were nursing home patients in Washington State on February 28. Numerous accounts of similar outbreaks soon followed, including 47 deaths at a nursing home in Minnesota (as of April 30), 54 deaths at a nursing home in Massachusetts (as of May 4), and 81 deaths at a facility in New Jersey (as of May 27).
Shared Savings Models Could Yield Part B Savings
“The establishment of a shared savings model has the potential to increase health care savings, biologic competition, and biosimilar utilization if implemented in Medicare Part B, according to Alex Brill, founder of Matrix Global Advisors (MGA) and a resident fellow at the American Enterprise Institute (AEI), who makes the case in a new research paper.”
New MGA White Paper Explores Lessons for the United States from Europe’s Biosimilar Experience
As the United States marks the tenth anniversary of the establishment of a biosimilars pathway, many experts express frustration that the US lags behind
Europe. A new white paper from Matrix Global Advisors carefully examines the US and European biosimilars markets and finds that the comparison between the markets is nuanced.
Six Reasons Why Now Is A Good Time To Consider An ESOP
“…net employment at ESOPs climbed over 60% during 2001-2011 vs. no change elsewhere, concludes research by Alex Brill, CEO of consulting firm Matrix Global Advisors.”
New MGA Report on a Medicare Shared Savings Demonstration for Biosimilars
Matrix Global Advisors (MGA) today released a new report, “Shared Savings Demonstration for Biosimilars in Medicare: An Opportunity to Promote Biologic Drug Competition,” by MGA founder and CEO Alex Brill. The report identifies a unique opportunity in Medicare Part B to boost biosimilar utilization through the establishment of a shared savings demonstration model administered by the Centers for Medicare & Medicaid Services Innovation Center.
MGA’s Alex Brill on CNBC’s Squawk Box
“We want the program to work and I think that sadly what we’re seeing is that the program is working quite well. And I say sadly because we are seeing tens of millions of people process through that system and we’re going to continue to see that I think for the next few weeks as the backlogs in certain states get worked through…”
Small-Business Loan Fund May Run Dry Again. Is There Another Way?
“‘That could help accelerate the rebound if we can just kind of mothball the economy and then turn back on the same economy with the same manager-employee relationship,” said Alex Brill, a resident fellow at the right-leaning American Enterprise Institute.”
MGA’s Alex Brill Serves as a Panelist for “Biosimilars: Breaking Through the Barriers” Symposium
Alex Brill was one of the panelists discussing his “commitment to expand biosimilar use in the United States and how physicians and government officials are looking to help.
Efforts to Combat E-Cigarette Misuse Could Backfire
Recent news about e-cigarette misuse has fueled both public misperception and policy responses that are likely to have unintended consequences. As the US vaping market continues to evolve, policymakers face the tricky challenge of safeguarding the potential for positive public health outcomes from e-cigarettes, which offer a lower-risk alternative to traditional cigarettes, while ensuring reasonable protections against youth use.
New MGA Paper Investigates the Economic and Budgetary Effects of the BLOCKING Act
This report examines the BLOCKING Act and why it is a misguided attempt at promoting generic drug competition.
MGA’s Alex Brill on CNBC’s Squawk Box
In anticipation of the December jobs report number being released later in the morning, Brill joins the morning news program to discuss his predictions that the number “will be right on the quarterly trend.”
MGA’s Alex Brill on Liberty & Justice for All
“I advocate and support a carbon tax, but not just blindly, not just any carbon tax. It is critically important that the carbon tax be revenue neutral. That at the time at which this policy is put in place its done in a matter in which the revenues expected to be generated from the carbon tax are used to reduce other taxes that are more distortionary. This is what we would call the principles of basic tax reform.”
MGA’s Alex Brill on CNBC’s Squawk Box
MGA’s Alex Brill on CNBC’s Squawk Box On this episode of 'Squawk Box,' Brill discusses Bill Gate's reaction to Senator...
- ‘Facing the Future’: Alex Brill discusses tax code and budget challenges
- 2026 Portman Center Symposium: Building an Achievable Fiscal Policy
- Senator Booker’s Costly Standard Deduction Proposal Would Reduce Charitable Giving
- FDA Continues to Expedite Biosimilar Development
- Diminishing Returns from the Government’s Drug Negotiation Program
- Would Senate Passage of an ACA Tax Credit Extension Matter?
- MGA Brief Examines State and Federal PBM Mandates
- FDA Moves to Facilitate Biosimilar Development
- How Pharmaceutical Tariffs Will Affect US Health Care Costs
- MGA Releases New Report Quantifying the Economic Impact of Healthcare Distributors
